StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Cyclacel Pharmaceuticals Trading Down 4.4 %
Shares of NASDAQ CYCC opened at $0.83 on Tuesday. Cyclacel Pharmaceuticals has a twelve month low of $0.75 and a twelve month high of $10.12. The firm has a 50-day moving average of $1.04 and a two-hundred day moving average of $1.56. The company has a market capitalization of $1.79 million, a price-to-earnings ratio of -0.05 and a beta of 0.51.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative net margin of 21,963.75% and a negative return on equity of 1,901.11%. During the same quarter in the previous year, the business earned ($6.60) earnings per share. As a group, research analysts predict that Cyclacel Pharmaceuticals will post -2.29 earnings per share for the current year.
Institutional Investors Weigh In On Cyclacel Pharmaceuticals
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Featured Articles
- Five stocks we like better than Cyclacel Pharmaceuticals
- What is MarketRankā¢? How to Use it
- Texas Roadhouse Stock Steering for New Highs This Year
- The Significance of Brokerage Rankings in Stock Selection
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Invest in Insurance Companies: A GuideĀ
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.